Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine to reduce renal ischemia-reperfusion injury in CABG with CPB
ChiCTR2100051804Phase 3Completed
- Sponsor
- First Affiliated Hospital of Bengbu Medical University
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of dexmedetomidine in acute kidney failure (AKF) and Kidney ischemia reperfusion injury (2 arms), sponsored by First Affiliated Hospital of Bengbu Medical University. Primary endpoints: superoxide dismutase, malondialdehyde and 7 more. Started Oct 2021; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
acute kidney failure (AKF)Kidney ischemia reperfusion injury
Beyond the preview
Go deeper on ChiCTR2100051804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051804.